BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 22390279)

  • 1. Polo-like kinase 1 (PLK1) inhibition suppresses cell growth and enhances radiation sensitivity in medulloblastoma cells.
    Harris PS; Venkataraman S; Alimova I; Birks DK; Donson AM; Knipstein J; Dubuc A; Taylor MD; Handler MH; Foreman NK; Vibhakar R
    BMC Cancer; 2012 Mar; 12():80. PubMed ID: 22390279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polo-Like Kinase 1 Pharmacological Inhibition as Monotherapy or in Combination: Comparative Effects of Polo-Like Kinase 1 Inhibition in Medulloblastoma Cells.
    Pezuk JA; Brassesco MS; Ramos PMM; Scrideli CA; Tone LG
    Anticancer Agents Med Chem; 2017; 17(9):1278-1291. PubMed ID: 28270075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Personalizing the treatment of pediatric medulloblastoma: Polo-like kinase 1 as a molecular target in high-risk children.
    Triscott J; Lee C; Foster C; Manoranjan B; Pambid MR; Berns R; Fotovati A; Venugopal C; O'Halloran K; Narendran A; Hawkins C; Ramaswamy V; Bouffet E; Taylor MD; Singhal A; Hukin J; Rassekh R; Yip S; Northcott P; Singh SK; Dunham C; Dunn SE
    Cancer Res; 2013 Nov; 73(22):6734-44. PubMed ID: 24019381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Small interfering RNA library screen identified polo-like kinase-1 (PLK1) as a potential therapeutic target for breast cancer that uniquely eliminates tumor-initiating cells.
    Hu K; Law JH; Fotovati A; Dunn SE
    Breast Cancer Res; 2012 Feb; 14(1):R22. PubMed ID: 22309939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of cyclin-dependent kinase 6 suppresses cell proliferation and enhances radiation sensitivity in medulloblastoma cells.
    Whiteway SL; Harris PS; Venkataraman S; Alimova I; Birks DK; Donson AM; Foreman NK; Vibhakar R
    J Neurooncol; 2013 Jan; 111(2):113-21. PubMed ID: 23138228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting polo-like kinase 1 enhances radiation efficacy for head-and-neck squamous cell carcinoma.
    Gerster K; Shi W; Ng B; Yue S; Ito E; Waldron J; Gilbert R; Liu FF
    Int J Radiat Oncol Biol Phys; 2010 May; 77(1):253-60. PubMed ID: 20394857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polo-like kinase 1 inhibition kills glioblastoma multiforme brain tumor cells in part through loss of SOX2 and delays tumor progression in mice.
    Lee C; Fotovati A; Triscott J; Chen J; Venugopal C; Singhal A; Dunham C; Kerr JM; Verreault M; Yip S; Wakimoto H; Jones C; Jayanthan A; Narendran A; Singh SK; Dunn SE
    Stem Cells; 2012 Jun; 30(6):1064-75. PubMed ID: 22415968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel PLK1 inhibitor onvansertib effectively sensitizes MYC-driven medulloblastoma to radiotherapy.
    Wang D; Veo B; Pierce A; Fosmire S; Madhavan K; Balakrishnan I; Donson A; Alimova I; Sullivan KD; Joshi M; Erlander M; Ridinger M; Foreman NK; Venkataraman S; Vibhakar R
    Neuro Oncol; 2022 Mar; 24(3):414-426. PubMed ID: 34477871
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of polo-like kinase 1 leads to the suppression of osteosarcoma cell growth in vitro and in vivo.
    Liu X; Choy E; Harmon D; Yang S; Yang C; Mankin H; Hornicek FJ; Duan Z
    Anticancer Drugs; 2011 Jun; 22(5):444-53. PubMed ID: 21399492
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PLK1 Inhibition Sensitizes Breast Cancer Cells to Radiation via Suppressing Autophagy.
    Wang B; Huang X; Liang H; Yang H; Guo Z; Ai M; Zhang J; Khan M; Tian Y; Sun Q; Mao Z; Zheng R; Yuan Y
    Int J Radiat Oncol Biol Phys; 2021 Jul; 110(4):1234-1247. PubMed ID: 33621661
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Small molecule inhibition of polo-like kinase 1 by volasertib (BI 6727) causes significant melanoma growth delay and regression in vivo.
    Cholewa BD; Ndiaye MA; Huang W; Liu X; Ahmad N
    Cancer Lett; 2017 Jan; 385():179-187. PubMed ID: 27793694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined gene expression profiling and RNAi screening in clear cell renal cell carcinoma identify PLK1 and other therapeutic kinase targets.
    Ding Y; Huang D; Zhang Z; Smith J; Petillo D; Looyenga BD; Feenstra K; Mackeigan JP; Furge KA; Teh BT
    Cancer Res; 2011 Aug; 71(15):5225-34. PubMed ID: 21642374
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The natural product Aristolactam AIIIa as a new ligand targeting the polo-box domain of polo-like kinase 1 potently inhibits cancer cell proliferation.
    Li L; Wang X; Chen J; Ding H; Zhang Y; Hu TC; Hu LH; Jiang HL; Shen X
    Acta Pharmacol Sin; 2009 Oct; 30(10):1443-53. PubMed ID: 19801998
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological inhibition of Polo-like kinase 1 (PLK1) by BI-2536 decreases the viability and survival of hamartin and tuberin deficient cells via induction of apoptosis and attenuation of autophagy.
    Valianou M; Cox AM; Pichette B; Hartley S; Paladhi UR; Astrinidis A
    Cell Cycle; 2015; 14(3):399-407. PubMed ID: 25565629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro biological activity of a novel small-molecule inhibitor of polo-like kinase 1.
    Lansing TJ; McConnell RT; Duckett DR; Spehar GM; Knick VB; Hassler DF; Noro N; Furuta M; Emmitte KA; Gilmer TM; Mook RA; Cheung M
    Mol Cancer Ther; 2007 Feb; 6(2):450-9. PubMed ID: 17267659
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of polo-like kinase 1 promotes hyperthermia sensitivity via inactivation of heat shock transcription factor 1 in human retinoblastoma cells.
    Yunoki T; Tabuchi Y; Hayashi A; Kondo T
    Invest Ophthalmol Vis Sci; 2013 Dec; 54(13):8353-63. PubMed ID: 24366665
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polo-like kinase 1 (Plk1) is expressed by cutaneous T-cell lymphomas (CTCLs), and its downregulation promotes cell cycle arrest and apoptosis.
    Nihal M; Stutz N; Schmit T; Ahmad N; Wood GS
    Cell Cycle; 2011 Apr; 10(8):1303-11. PubMed ID: 21436619
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo.
    Steegmaier M; Hoffmann M; Baum A; Lénárt P; Petronczki M; Krssák M; Gürtler U; Garin-Chesa P; Lieb S; Quant J; Grauert M; Adolf GR; Kraut N; Peters JM; Rettig WJ
    Curr Biol; 2007 Feb; 17(4):316-22. PubMed ID: 17291758
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mitotic arrest and slippage induced by pharmacological inhibition of Polo-like kinase 1.
    Raab M; Krämer A; Hehlgans S; Sanhaji M; Kurunci-Csacsko E; Dötsch C; Bug G; Ottmann O; Becker S; Pachl F; Kuster B; Strebhardt K
    Mol Oncol; 2015 Jan; 9(1):140-54. PubMed ID: 25169932
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibiting polo-like kinase 1 enhances radiosensitization via modulating DNA repair proteins in non-small-cell lung cancer.
    Yao D; Gu P; Wang Y; Luo W; Chi H; Ge J; Qian Y
    Biochem Cell Biol; 2018 Jun; 96(3):317-325. PubMed ID: 29040814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.